By Fineline Cube Biogen Inc. (NASDAQ: BIIB) has finalized an agreement with TJ Biopharma, a China-based biopharmaceutical company, to acquire exclusive rights to felzartamab—a CD38-targeting monoclonal antibody—in Greater China. The transaction marks the final step in Biogen’s consolidation of global ownership of the asset, resolving a multi-layered chain of prior licensing arrangements.
Deal Terms & Financial Structure
| Component | Detail |
|---|---|
| Upfront Payment | $100 million (to be recorded as IPR&D expense in Q2 2026) |
| Milestone Payments | Up to $750 million tied to development, regulatory, and commercial achievements |
| Royalties | Mid-single-digit to low-double-digit tiered percentages on net sales in Greater China |
| Assumed Obligations | Biogen will also assume milestone and royalty commitments originally owed by MorphoSys to its partners under prior agreements |
Asset History & Rights Consolidation
- Origin: Felzartamab was discovered and initially developed by MorphoSys AG (acquired by Novartis in 2022)
- Nov 2017: TJ Biopharma licensed Greater China rights
- Jun 2022: MorphoSys granted ex-China rights to HiBio
- May 2024: Biogen acquired HiBio for $1.8 billion, gaining all rights outside Greater China
- Apr 2026: Acquisition of Greater China rights from TJ Biopharma completes 100% global control
This strategic closure eliminates future royalty leakage and streamlines development, manufacturing, and commercialization under a single sponsor—critical for lifecycle management and partnership negotiations.
Strategic Rationale
- Portfolio Synergy: Felzartamab complements Biogen’s growing immunology and hematology pipeline, particularly in autoimmune and plasma cell disorders
- Global Development Efficiency: Unified control enables harmonized clinical trials, regulatory filings, and supply chain operations
- Monetization Flexibility: Full ownership enhances optionality for co-development or out-licensing in non-core markets
Felzartamab is currently in Phase II trials for IgG4-related disease and primary membranous nephropathy, with potential expansion into multiple myeloma and other CD38-expressing conditions.
Market Context
The deal reflects a broader trend of Western biotechs repatriating global rights to high-value assets originally out-licensed during capital-constrained phases. For TJ Biopharma, the upfront provides non-dilutive funding to advance its internal pipeline, including oncology and metabolic programs.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial impact, development plans, and strategic benefits. Actual results may vary due to clinical outcomes, regulatory decisions, and market dynamics.-Fineline Info & Tech